Core Viewpoint - The company Zhongguang Nuclear Technology announced plans to produce various isotopes, indicating a strategic move towards expanding its product offerings in the isotope market [2] Group 1: Product Development - The isotope company plans to primarily produce germanium-gallium generators, germanium-68, and iodine-123, with the capability for mass production and stable delivery based on customer orders [2] - The company is actively advancing the research and development of copper-64 and zirconium-89 processing technologies [2] - Lutetium-177 is currently only available as an agency sales product, with no plans for independent production at this time [2]

（文章来源：证券日报） 证券日报网讯中广核技11月3日发布公告，在公司回答调研者提问时表示，国产替代方面，公司高度重 视同位素国产替代战略，目前核心产品锗镓发生器正处于从技术攻关到规模化供应的关键时期。同位素 产业具有技术壁垒高、审批流程严、产业链协同复杂的特性，从技术突破到市场落地需经历靶料制备、 辐照技术、分离纯化、质量认证等多环节验证，公司正在稳步推进相关工作。市场开发方面，公司将推 行"政策协同-客户绑定-生态共建"的三维市场策略，积极参与行业团体标准编制，联动医疗机构开展科 研合作和临床培训，加速市场开拓。 ...

Group 1: Proton Medical Equipment and Isotope Production - Proton medical equipment from the Huaxi project has completed factory production, but installation is pending site readiness, with no acceptance expected this year [2] - The company is focusing on domestic isotope production, particularly the germanium-gallium generator, which is in a critical phase from technical breakthroughs to large-scale supply [2][3] - The company plans to produce isotopes such as germanium-68 and iodine-123, with stable delivery based on customer orders once production starts [3] Group 2: Research and Development Investments - The company has developed a high-power industrial irradiation electron accelerator for disinfection, which offers higher power and efficiency compared to traditional models [4] - New materials like XETFE, suitable for aerospace applications, have been developed, achieving small-scale sales and targeting both domestic and international markets [7] - The company is also advancing in the production of copper-64 and zirconium-89 isotopes, with plans for future industrialization based on market demand [4] Group 3: Financial Performance and Strategic Measures - The company has faced two consecutive years of losses but is implementing measures to reduce costs and increase revenue, including strategic collaborations with major clients [8] - Plans for product transformation and innovation enhancement are underway to align with market demands [8] - The company aims to improve operational efficiency through comprehensive reforms [8]